The Pharmaletter

One To Watch

alaxia_company

Alaxia

This private French biotech is an affiliate of the Stragen Healthcare Group developing therapeutic solutions for respiratory diseases based on its proprietary peroxidase platform..

The most advanced drug candidate, ALX-009, is an antimicrobial innovative compound aiming at treating cystic fibrosis, including the most resistant bacterial strains.

In October 2019, Alaxia joined the inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis consortium as a partner, in order to advance the development of ALX-009, which can be used as a standalone therapy or as an adjunctive to antibiotics.

ALX-009 is in the final stages of Phase I in cystic fibrosis and bronchiectasis trials. Patient enrolment in Phase IIa trials is planned to start in 2020.

Want to Update your Company's Profile?


Latest Alaxia News

More Alaxia news >